PE20191493A1 - Receptores de linfocitos t e inmuno terapias basadas en el uso de los mismos contra canceres positivos para prame - Google Patents

Receptores de linfocitos t e inmuno terapias basadas en el uso de los mismos contra canceres positivos para prame

Info

Publication number
PE20191493A1
PE20191493A1 PE2019001902A PE2019001902A PE20191493A1 PE 20191493 A1 PE20191493 A1 PE 20191493A1 PE 2019001902 A PE2019001902 A PE 2019001902A PE 2019001902 A PE2019001902 A PE 2019001902A PE 20191493 A1 PE20191493 A1 PE 20191493A1
Authority
PE
Peru
Prior art keywords
antigen
recognizing constructs
taa
tcr
same against
Prior art date
Application number
PE2019001902A
Other languages
English (en)
Inventor
Sebastian Bunk
Leonie Alten
Mathias Ferber
Claudia Wagner
Dominik Maurer
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102017106305.6A external-priority patent/DE102017106305A1/de
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PE20191493A1 publication Critical patent/PE20191493A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464489—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invencion atane a constructos reconocedores de antigeno dirigidos contra antigenos asociados a tumores (TAA), en particular contra el antigeno expresado preferencialmente en el melanoma (PRAME, por sus siglas en ingles). La invencion proporciona en concreto moleculas basadas en un nuevo receptor de linfocitos T (TCR) que son selectivas y especificas hacia el antigeno de la invencion que es expresado por tumores. El TCR de la invencion, asi como los fragmentos de union con el T AA que derivan del mismo, estan destinados al uso en el diagnostico, el tratamiento y la prevencion de enfermedades tumorales que expresan el TAA. Ademas, se proporcionan acidos nucleicos que codifican los constructos reconocedores del antigeno de la invencion, los vectores que comprenden esos acidos nucleicos, las celulas recombinantes que expresan los constructos reconocedores del antigeno y las composiciones farmaceuticas que comprenden los compuestos de la invencion.
PE2019001902A 2017-03-23 2018-03-23 Receptores de linfocitos t e inmuno terapias basadas en el uso de los mismos contra canceres positivos para prame PE20191493A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762475329P 2017-03-23 2017-03-23
DE102017106305.6A DE102017106305A1 (de) 2017-03-23 2017-03-23 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
PCT/EP2018/057482 WO2018172533A2 (en) 2017-03-23 2018-03-23 T cell receptors and immune therapy using the same against prame positive cancers

Publications (1)

Publication Number Publication Date
PE20191493A1 true PE20191493A1 (es) 2019-10-21

Family

ID=61899213

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001902A PE20191493A1 (es) 2017-03-23 2018-03-23 Receptores de linfocitos t e inmuno terapias basadas en el uso de los mismos contra canceres positivos para prame

Country Status (17)

Country Link
US (2) US11236145B2 (es)
EP (1) EP3600409A2 (es)
JP (2) JP2020511152A (es)
KR (1) KR20190132655A (es)
CN (1) CN110494160A (es)
AU (1) AU2018240501A1 (es)
BR (1) BR112019019523A2 (es)
CA (1) CA3056493A1 (es)
CL (1) CL2019002645A1 (es)
CO (1) CO2019011688A2 (es)
CR (1) CR20190482A (es)
IL (2) IL269578B1 (es)
MX (2) MX2019011260A (es)
PE (1) PE20191493A1 (es)
PH (1) PH12019502151A1 (es)
SG (1) SG11201908023YA (es)
TW (1) TWI799922B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3670530A1 (en) * 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CA3130618A1 (en) * 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
KR20220017892A (ko) * 2019-05-08 2022-02-14 얀센 바이오테크 인코포레이티드 T세포 매개 면역의 조절을 위한 물질 및 방법
PE20220164A1 (es) 2019-05-27 2022-01-28 Immatics Us Inc Vectores viricos y uso de los mismos en terapias celulares adoptivas
MX2022010461A (es) 2020-02-24 2022-12-13 Immatics Us Inc Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas.
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022017435A1 (zh) * 2020-07-22 2022-01-27 信达生物制药(苏州)有限公司 一系列TCR-β链的CDR3序列中共有序列的生物标志物及其应用
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
CA3217738A1 (en) 2021-05-05 2022-05-04 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
CN117980326A (zh) 2021-07-14 2024-05-03 2赛文缇生物公司 与来自抗体的结合结构域融合的经工程化的t细胞受体
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
US20230190807A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Tcr compounds, compositions, and methods of treating
CN113817044B (zh) * 2021-10-14 2023-10-13 深圳大学总医院 T细胞受体、相关工程化细胞及其应用
CN113789304B (zh) * 2021-10-14 2023-03-31 深圳大学总医院 高亲和力tcr及其应用
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
WO2023196996A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN115073584B (zh) * 2022-05-07 2023-10-20 溧阳瑅赛生物医药有限公司 一种特异性识别prame抗原肽的tcr及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105968191A (zh) 2011-06-28 2016-09-28 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
RU2578009C2 (ru) 2013-05-08 2016-03-20 Закрытое акционерное общество "ЕВРОГЕН" Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках
WO2016011210A2 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
EP4201955A1 (en) 2015-03-10 2023-06-28 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
CN106084036A (zh) 2015-11-02 2016-11-09 广州市香雪制药股份有限公司 识别prame抗原短肽的t细胞受体
CN106519019B (zh) 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
CN106478809B (zh) 2015-11-06 2018-06-01 广东香雪精准医疗技术有限公司 识别prame抗原短肽的tcr
CN106831978B (zh) 2015-12-04 2020-05-26 中国科学院广州生物医药与健康研究院 识别prame抗原的t细胞受体
CN106699874B (zh) 2016-03-29 2018-06-05 广东香雪精准医疗技术有限公司 识别prame抗原短肽的t细胞受体
ES2949342T3 (es) 2016-06-17 2023-09-27 Medigene Immunotherapies Gmbh Receptores de células T y usos de los mismos
DE102017106305A1 (de) * 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten

Also Published As

Publication number Publication date
TWI799922B (zh) 2023-04-21
CN110494160A (zh) 2019-11-22
MX2023003463A (es) 2023-04-19
BR112019019523A2 (pt) 2020-04-22
US20220098270A1 (en) 2022-03-31
KR20190132655A (ko) 2019-11-28
US11236145B2 (en) 2022-02-01
JP2023088973A (ja) 2023-06-27
EP3600409A2 (en) 2020-02-05
CL2019002645A1 (es) 2019-12-13
US20180273602A1 (en) 2018-09-27
PH12019502151A1 (en) 2020-06-29
JP2020511152A (ja) 2020-04-16
AU2018240501A1 (en) 2019-10-31
IL310552A (en) 2024-03-01
IL269578A (en) 2019-11-28
CA3056493A1 (en) 2018-09-27
IL269578B1 (en) 2024-03-01
SG11201908023YA (en) 2019-10-30
CR20190482A (es) 2020-01-07
MX2019011260A (es) 2019-12-05
TW202208420A (zh) 2022-03-01
CO2019011688A2 (es) 2020-02-28

Similar Documents

Publication Publication Date Title
PE20191493A1 (es) Receptores de linfocitos t e inmuno terapias basadas en el uso de los mismos contra canceres positivos para prame
CO2020000357A2 (es) Receptores de células t novedosos, e inmunoterapia usando los mismos
CR20190095A (es) Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos
CO2020006905A2 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos
CR20190278A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
CL2019001535A1 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza.
WO2018172533A3 (en) T cell receptors and immune therapy using the same against prame positive cancers
CL2019000366A1 (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
CR20190276A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
DOP2018000212A (es) Moléculas de unión a bcma y métodos de uso de las mismas
CL2019003310A1 (es) Nuevos péptidos (seq id no:1) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124)
PE20200152A1 (es) Receptores de union a antigeno mejorados
PE20230768A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon amicrocitico y otros tipos de cancer
CR20180074A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer
PE20171790A1 (es) Anticuerpos anti-ceacam6 y sus usos
PE20181075A1 (es) Nuevos pepticos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia linfocitica cronica (llc) y otros tipos de cancer
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
CL2017003361A1 (es) Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres
PE20211643A1 (es) Inmunoterapia con peptidos restringidos a a 01 y una combinacion de peptidos contra el cancer y metodos relacionados
CL2019000460A1 (es) Nuevos péptidos y estructuras de soporte para el uso en la inmunoterapia contra el carcinoma epidermoide de cabeza y cuello y otros tipos de cáncer.
CL2019003326A1 (es) Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso de la inmunoterapia del mieloma y de otros tipos de cáncer. (divisional solicitud 201703244)
CO2019002229A2 (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
AR109345A1 (es) Receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
AR113834A1 (es) Receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos
CR20180530A (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cancer